NattoPharma

Heart health studies

MenaQ7® has been shown in clinical study to improve arterial elasticity, making them more flexible.

Cardiovascular disease is the frequent cause of rapid deterioration of health and even death, and is often due to the calcification of blood vessels (vascular calcification), especially in the coronary arteries of the heart. Research on human volunteers has unequivocally linked the role of Vitamin K2 to the inhibition of vascular calcification and the improvement of arterial elasticity.

Calcification is potentially a dangerous condition that, when combined with deposits of fat in the arteries, causes clogging of the blood vessels and may result in myocardial infarction (heart attack), angina pectoris (chest pain), and thrombosis (blood clots).

Human trials have directly measured the positive effect of Vitamin K2 on cardiovascular health, which is not observed with Vitamin K1. NattoPharma is involved in cutting-edge research, understanding further how Vitamin K2 plays critical functions, including how matrix Gla protein (MGP) is now understood to be the most potent modulator of vascular calcification, provided the body has enough Vitamin K2 to activate it.

For more detail on this exciting information on the link between MenaQ7® consumption to cardiovascular health, visit http://menaq7.com/health-benefits/cardiovascular-health/

Contact Us

For further information regarding NattoPharma’s R&D activities, please contact:

William Sommer

VP, Global Development & Regulatory

william.sommer@nattopharma.com

NattoPharma contact information:
Main office: Lilleakerveien 2B, 0283 Oslo,Norway
North American Subsidary: 328 Amboy Ave.,Ste. D,Metuchen, NJ 08840
Tel: (+47) 40 00 90 08
Tel: (+1) 609-454-2992
E-mail: info@nattopharma.com
E-mail: info.US@nattopharma.com
Created by:
Nutricon logo.
Search term:
Newsletter